Get started
Author

Kara Higgins

Observed name: K. Higgins
Observed institution: AstraZeneca (United States)
OpenAlex ID: A5026397606
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
2021 · John C. Byrd, Peter Hillmen, et al. · Journal of Clinical Oncology · 673
PDF
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
2023 · John F. Seymour, John C. Byrd, et al. · Blood · 143
PDF
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
2021 · John C. Byrd, Peter Hillmen, et al. · Journal of Clinical Oncology · 39
A phase 2, multicentre, open‐label trial ( ACE‐LY ‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
2022 · Paolo Strati, Morton Coleman, et al. · British Journal of Haematology · 34
PDF
First Results of a Head‐to‐head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
2021 · P. Hillmen, J. C. Byrd, et al. · Hematological Oncology · 8
Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
2022 · Paolo Strati, Beth Christian, et al. · Blood · 6
Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
2021 · John F. Seymour, John C. Byrd, et al. · Blood · 3
Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
2022 · John F. Seymour, John C. Byrd, et al. · Blood · 2
Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
2022 · L Elizabeth Budde, Morton Coleman, et al. · Journal of Clinical Oncology · 1
CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
2021 · John C. Byrd, Peter Hillmen, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
P1129: Acalabrutinib in Patients With Relapsed/refractory (r/r) Marginal Zone Lymphoma (mzl): Results of a Phase 2, Multicenter, Open-label Trial
2022 · P. Strati, M. Coleman, et al. · HemaSphere
Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
2021 · John C. Byrd, Peter Hillmen, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 12
Citation count: 909
H-index: 6
I10-index: 4
Year
Topic
Type